Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005164818 | Thyroid | ATC | vesicle localization | 91/6293 | 177/18723 | 7.21e-07 | 9.64e-06 | 91 |
GO:006099623 | Thyroid | ATC | dendritic spine development | 57/6293 | 99/18723 | 8.24e-07 | 1.09e-05 | 57 |
GO:006099815 | Thyroid | ATC | regulation of dendritic spine development | 36/6293 | 61/18723 | 4.10e-05 | 3.32e-04 | 36 |
GO:010602716 | Thyroid | ATC | neuron projection organization | 50/6293 | 93/18723 | 4.87e-05 | 3.88e-04 | 50 |
GO:004881315 | Thyroid | ATC | dendrite morphogenesis | 71/6293 | 146/18723 | 1.18e-04 | 8.38e-04 | 71 |
GO:009706115 | Thyroid | ATC | dendritic spine organization | 45/6293 | 84/18723 | 1.27e-04 | 9.03e-04 | 45 |
GO:009917314 | Thyroid | ATC | postsynapse organization | 78/6293 | 168/18723 | 3.66e-04 | 2.26e-03 | 78 |
GO:006100114 | Thyroid | ATC | regulation of dendritic spine morphogenesis | 27/6293 | 47/18723 | 6.69e-04 | 3.77e-03 | 27 |
GO:006099712 | Thyroid | ATC | dendritic spine morphogenesis | 33/6293 | 61/18723 | 7.76e-04 | 4.28e-03 | 33 |
GO:009917512 | Thyroid | ATC | regulation of postsynapse organization | 44/6293 | 90/18723 | 1.89e-03 | 9.27e-03 | 44 |
GO:009951813 | Thyroid | ATC | vesicle cytoskeletal trafficking | 35/6293 | 73/18723 | 7.71e-03 | 3.00e-02 | 35 |
GO:005080712 | Thyroid | ATC | regulation of synapse organization | 87/6293 | 211/18723 | 1.20e-02 | 4.27e-02 | 87 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TANC2 | SNV | Missense_Mutation | | c.2858G>T | p.Cys953Phe | p.C953F | Q9HCD6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TANC2 | SNV | Missense_Mutation | rs568898605 | c.2705N>G | p.Ala902Gly | p.A902G | Q9HCD6 | protein_coding | tolerated(0.13) | benign(0.029) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TANC2 | SNV | Missense_Mutation | | c.5449N>A | p.Glu1817Lys | p.E1817K | Q9HCD6 | protein_coding | tolerated_low_confidence(0.07) | benign(0.01) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TANC2 | SNV | Missense_Mutation | novel | c.4835N>C | p.Ile1612Thr | p.I1612T | Q9HCD6 | protein_coding | deleterious_low_confidence(0) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TANC2 | SNV | Missense_Mutation | novel | c.4787T>C | p.Val1596Ala | p.V1596A | Q9HCD6 | protein_coding | tolerated_low_confidence(0.28) | benign(0.024) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TANC2 | SNV | Missense_Mutation | | c.2979N>T | p.Gln993His | p.Q993H | Q9HCD6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TANC2 | SNV | Missense_Mutation | | c.5311N>T | p.Pro1771Ser | p.P1771S | Q9HCD6 | protein_coding | tolerated_low_confidence(0.09) | probably_damaging(0.994) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
TANC2 | SNV | Missense_Mutation | rs568898605 | c.2705N>G | p.Ala902Gly | p.A902G | Q9HCD6 | protein_coding | tolerated(0.13) | benign(0.029) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TANC2 | SNV | Missense_Mutation | | c.5350C>T | p.Pro1784Ser | p.P1784S | Q9HCD6 | protein_coding | tolerated_low_confidence(0.38) | possibly_damaging(0.508) | TCGA-B6-A0IH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TANC2 | SNV | Missense_Mutation | | c.3544G>A | p.Val1182Ile | p.V1182I | Q9HCD6 | protein_coding | deleterious(0.02) | possibly_damaging(0.565) | TCGA-B6-A0WS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |